We Offer Worldwide Shipping
Login Wishlist

Ginsenoside Rg5

$800

  • Brand : BIOFRON

  • Catalogue Number : BD-D0354

  • Specification : HPLC≥98%

  • CAS number : 186763-78-0

  • Formula : C42H70O12

  • Molecular Weight : 767

  • PUBCHEM ID : 11550001

  • Volume : 20mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-D0354

Analysis Method

Specification

HPLC≥98%

Storage

-20℃

Molecular Weight

767

Appearance

Powder

Botanical Source

This product is isolated and purified from the roots of Panax ginseng C. A. Mey.

Structure Type

Category

SMILES

CC(=CCC=C(C)C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)C)O)C)C

Synonyms

β-D-Glucopyranoside, (3β,12β,20E)-12-hydroxydammara-20(22),24-dien-3-yl 2-O-β-D-glucopyranosyl-/(3β,12β,20E)-12-Hydroxydammara-20(22),24-dien-3-yl 2-O-β-D-glucopyranosyl-β-D-glucopyranoside/Ginsenoside Rg5

IUPAC Name

Density

1.3±0.1 g/cm3

Solubility

Methanol

Flash Point

471.2±34.3 °C

Boiling Point

855.6±65.0 °C at 760 mmHg

Melting Point

InChl

InChl Key

NJUXRKMKOFXMRX-RNCAKNGISA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:186763-78-0) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

21578582

Abstract

The title complex, [Fe2(C2H5S)3(C12H21Si)2], has an unusual Fe2S3 core. The two 1,2,3,4-tetra­methyl-5-(trimethyl­silyl)cyclo­penta­dienyl (Cp′) ligands coordinate to the Fe atoms with their C5 planes perpendicular [dihedral angles = 88.23 (7) and 88.55 (7)°] to the Fe—Fe vector, building two Cp′Fe subunits. These two subunits are bridged by three thiol­ate ligands. There are no significant differences in the coordination geometries between the two Fe atoms. The short Fe—Fe distance of 2.7842 (5) a is clear evidence of an inter­metallic bond. Such a diiron-sulfur structure might act as a model of active sites in some metalloproteins.

Title

Tri-μ-ethanethiol­ato-bis­{[η5-1,2,3,4-tetra­methyl-5-(trimethyl­silyl)cyclo­penta­dien­yl]iron(II,III)}(FeII-FeIII)

Author

Jing Lia,*

Publish date

2009 Nov 7.

PMID

20962127

Abstract

Objective
Active drug safety surveillance may be enhanced by analysis of multiple observational healthcare databases, including administrative claims and electronic health records. The objective of this study was to develop and evaluate a common data model (CDM) enabling rapid, comparable, systematic analyses across disparate observational data sources to identify and evaluate the effects of medicines.

Design
The CDM uses a person-centric design, with attributes for demographics, drug exposures, and condition occurrence. Drug eras, constructed to represent periods of persistent drug use, are derived from available elements from pharmacy dispensings, prescriptions written, and other medication history. Condition eras aggregate diagnoses that occur within a single episode of care. Drugs and conditions from source data are mapped to biomedical ontologies to standardize terminologies and enable analyses of higher-order effects.

Measurements
The CDM was applied to two source types: an administrative claims and an electronic medical record database. Descriptive statistics were used to evaluate transformation rules. Two case studies demonstrate the ability of the CDM to enable standard analyses across disparate sources: analyses of persons exposed to rofecoxib and persons with an acute myocardial infarction.

Results
Over 43 million persons, with nearly 1 billion drug exposures and 3.7 billion condition occurrences from both databases were successfully transformed into the CDM. An analysis routine applied to transformed data from each database produced consistent, comparable results.

Conclusion
A CDM can normalize the structure and content of disparate observational data, enabling standardized analyses that are meaningfully comparable when assessing the effects of medicines.

KEYWORDS

Pharmacoepidemiology, product surveillance, Postmarketing, drug safety, medical records systems, computerized, Epidemiologic methods, drug Toxicity, databases, Factual, medical Informatics Computing

Title

Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases

Author

Stephanie J Reisinger,corresponding author1 Patrick B Ryan,2 Donald J O'Hara,1 Gregory E Powell,2 Jeffery L Painter,2 Edward N Pattishall,2 and Jonathan A Morris1

Publish date

2010 Nov-Dec;

PMID

30731458

Abstract

BACKGROUND/AIMS:
Although the cure rate for retinoblastoma is high, surviving patients are at risk for developing secondary cancers and require life-long follow-up. It is imperative to discover and develop novel therapeutic agents with better efficiency and fewer adverse effects. Ginsenoside-Rg5 is an active derivate from ginseng and exerts anti-cancer activity in breast cancer cells. However, it is still unclear whether ginsenoside-Rg5 has similar anti-cancer functions in retinoblastoma.

METHODS:
Retinoblastoma cells were treated with ginsenoside-Rg5, followed by MTT assay analysis of the cell viability, cell number assay and colony formation assay analyses of cell proliferation, and flow cytometric analysis of apoptosis. Gene mRNA levels and protein levels were determined by quantitative real-time PCR and Western blot, respectively.

RESULTS:
Ginsenoside-Rg5 inhibited retinoblastoma cell viability in a dose-dependent and time-dependent manner via preventing cell proliferation and inducing cell apoptosis. BCL2 expression was downregulated by ginsenoside-Rg5 treatment via inactivating the AKT signaling pathway. BCL2 overexpression completely eliminated the inhibitory effect of ginsenoside-Rg5 on cancer cell viability.

CONCLUSION:
Ginsenoside-Rg5 inhibits cell proliferation and induces apoptosis in retinoblastoma cells by inactivating the AKT signaling pathway, thereby downregulating BCL2 expression.

© 2019 S. Karger AG, Basel.

KEYWORDS

Apoptosis; BCL2; Cell proliferation; Ginsenoside-Rg5; Retinoblastoma

Title

Ginsenoside-Rg5 Inhibits Retinoblastoma Proliferation and Induces Apoptosis through Suppressing BCL2 Expression.

Author

Cui Y1, Su Y1, Deng L1, Wang W2.

Publish date

2018


Description :

Empty ...